Solventum Corporation (NYSE:SOLV) Holdings Trimmed by Boston Trust Walden Corp

Boston Trust Walden Corp lowered its holdings in Solventum Corporation (NYSE:SOLV) by 6.9% in the first quarter, Holdings Channel.com reports. The firm owned 3,370 shares of the company’s stock after selling 250 shares during the period. Boston Trust Walden Corp’s holdings in Solventum were worth $256,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of SOLV. Raymond James Financial Inc. acquired a new position in Solventum during the fourth quarter valued at $18,583,000. Van ECK Associates Corp grew its stake in Solventum by 28.7% during the 4th quarter. Van ECK Associates Corp now owns 47,224 shares of the company’s stock valued at $3,120,000 after acquiring an additional 10,530 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Solventum by 26.2% in the 4th quarter. Victory Capital Management Inc. now owns 67,654 shares of the company’s stock valued at $4,469,000 after purchasing an additional 14,065 shares during the period. Vontobel Holding Ltd. lifted its position in shares of Solventum by 11.6% in the fourth quarter. Vontobel Holding Ltd. now owns 5,292 shares of the company’s stock worth $350,000 after purchasing an additional 552 shares in the last quarter. Finally, Avantax Advisory Services Inc. lifted its position in shares of Solventum by 2.2% in the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after purchasing an additional 192 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Bank of America boosted their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. The Goldman Sachs Group boosted their price target on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. KeyCorp assumed coverage on shares of Solventum in a report on Friday, June 6th. They set a “sector weight” rating on the stock. Morgan Stanley upped their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th. Finally, Wells Fargo & Company lifted their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $80.29.

Solventum Stock Performance

Shares of SOLV opened at $73.50 on Friday. The firm has a market cap of $12.72 billion, a price-to-earnings ratio of 34.03, a price-to-earnings-growth ratio of 1.86 and a beta of 0.54. The company’s fifty day moving average is $70.66 and its 200-day moving average is $71.70. The company has a quick ratio of 0.85, a current ratio of 1.19 and a debt-to-equity ratio of 2.40. Solventum Corporation has a 12 month low of $47.16 and a 12 month high of $85.92.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.15. Solventum had a net margin of 4.55% and a return on equity of 31.01%. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.02 billion. During the same period in the prior year, the company posted $2.08 earnings per share. Solventum’s revenue for the quarter was up 2.7% on a year-over-year basis. Equities analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.